Click Here to return To Results

 

Acute Treatment of Migraine with Dihydroergotamine Nasal Spray Arch Neurol 53:1285-1291, Gallagher,R.M., 1996 See this aricle in Pubmed Article Abstract Self-administration of dihydroergotamine resulted in significant increased in pain relief and functional ability and significant decreased in pain intensity and nausea compared with the placebo.Among patients treated with 2 mg of dihydroergotamine mesylate,27%considered their migraine resolved (ie,no pain or mild pain)as early as 30 minutes after treatment.By 4 hours after treatment,70%of these patients'headaches were resolved.Headache pain returned within 24 hours in only 14%of patients whose headaches had been resolved.No serious adverse effects of dihydroergotamine treatment were observed,and the adverse events that did occur were primarily related to the route of administration.The 2-mg dihydroergotamine mesylate dose provided slightly superior pain relief and was associated with fewer adverse events compared with the 3-mg dihydroergotamine mesylate dose.The present results suggest that intranasal administration of dihydroergotamine represents an important new therapeutic option for migraine sufferers.

Related Tags

(click to filter results - removes previous filter) DHE headache,treatment of intranasal medication migraine migraine,treatment of nasal spray treatment of neurologic disorder

Click Here to return To Results